there was a report on Channel 10 news recently regards a first in Australia of endovascular repair of the Mitral valve in RPA . Anteris has a new such device under development. I believe the company does not wish to elaborate much at this stage before the tech is secured by patents. This area will grow to rival AVR. If the company was to sell the AVR tech to a major they could retain this mitral tech in the company and investors may not have to pay capital gain immediately. The MVR tech is very valuable and could earn many extra dollars for a complete sale IMHO. No advice.
AVR Price at posting:
$21.50 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)